A Randomized Controlled study of Daily ASA used with reduce fibrosis progression in Non-alcoholic fatty liver disease
Phase 2
Recruiting
- Conditions
- Fibrosis progression in Non-alcoholic fatty liver diseaseAspirin, Fibrosis progression, Non-alcoholic fatty liver disease
- Registration Number
- TCTR20230705001
- Lead Sponsor
- Internal medicine department, Phramongkutklao Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 82
Inclusion Criteria
1.Patients with diagnosis of non-alcoholic fatty liver disease
2.No history of aspirin used before
Exclusion Criteria
1.Hepatitis from other causes(viral hepatitis infection, autoimmune)
2.Excess alcohol drinking(140 gram/week in male, 70 gram/week in female) in 2 years before
3.Decompensated cirrhosis
4.Receive other medications(Tamoxifen, Methotrexate, Amiodarone, Valproic acid, Glucocorticoid) in 6 months before
5.Aspirin allergy
6.Pregnancy or breastfeeding
7.History of upper gastrointestinal hemorrhage
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver fibrosis at 3 and 6 months after end of the intervention Fibroscan,Alanine transaminase(ALT) at 3 and 6 months after end of the intervention Liver function test
- Secondary Outcome Measures
Name Time Method Change of score at 3 and 6 months after end of the intervention NAFLD fibrosis score, FIB-4 score, APRI index